Rangsima Lolekha1, Kulkanya Chokephaibulkit2, Nittaya Phanuphak3, Surasith Chaithongwongwatthana4, Sasisopin Kiertiburanakul5, Pleonchan Chetchotisakd6, Sarawut Boonsuk7. 1. Division of Global HIV and TB, Thailand Ministry of Public Health - U.S. CDC Collaboration, Nonthaburi 11000, Thailand. 2. Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand. 3. The Thai Red Cross AIDS Research Centre, Bangkok 10330, Thailand. 4. Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. 5. Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand. 6. Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. 7. Department of Health, Thailand Ministry of Public Health, Nonthaburi 11000, Thailand.
Abstract
BACKGROUND: Thailand has made progress in reducing perinatal HIV transmission rates to levels that meet the World Health Organization targets for so-called "elimination" (<2%) of mother-to-child transmission (MTCT). OBJECTIVES: To highlight the Thailand National Guidelines on HIV/AIDS Treatment Prevention Working Group issued a new version of its National Prevention of MTCT guidelines in March 2017 aimed to reduce MTCT rate to <1% by 2020. DISCUSSION OF GUIDELINES: The guidelines include recommending initiation of antepartum antiretroviral therapy (ART) containing tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC)/emtricitabine (FTC) plus efavirenz regardless of CD4 cell count as soon as HIV is diagnosed for ART naïve HIV-infected pregnant women. An alternative regimen is TDF or zidovudine (AZT) plus 3TC/FTC plus lopinavir/ritonavir (LPV/r) for HIV-infected pregnant women suspected resistant to non-nucleoside reverse transcriptase inhibitors. Treatment should be started immediately irrespective of gestational age and continued after delivery for life. Raltegravir is recommended in addition to the ART regimen for HIV-infected pregnant women who present late (gestational age (GA) ≥32 weeks) or those who have a viral load (VL) >1000 copies/mL at GA ≥32 weeks. HIV-infected pregnant women who conceive while receiving ART should continue their treatment regimen during pregnancy. HIV-infected pregnant women who present in labor and are not receiving ART should receive single-dose nevirapine immediately along with oral AZT, and continue ART for life. Infants born to HIV-infected mothers are categorized as high or standard risk for MTCT. High MTCT risk is defined as an infant whose mother has a viral load (VL) > 50 copies/mL at GA > 36 weeks or has received ART <12 weeks before delivery, or has poor ART adherence. These infants should be started on AZT plus 3TC plus NVP for 6 weeks after delivery. Infants with standard MTCT risk should receive AZT for 4 weeks. Formula feeding exclusively is recommended for all HIV-exposed infants.
BACKGROUND: Thailand has made progress in reducing perinatal HIV transmission rates to levels that meet the World Health Organization targets for so-called "elimination" (<2%) of mother-to-child transmission (MTCT). OBJECTIVES: To highlight the Thailand National Guidelines on HIV/AIDS Treatment Prevention Working Group issued a new version of its National Prevention of MTCT guidelines in March 2017 aimed to reduce MTCT rate to <1% by 2020. DISCUSSION OF GUIDELINES: The guidelines include recommending initiation of antepartum antiretroviral therapy (ART) containing tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC)/emtricitabine (FTC) plus efavirenz regardless of CD4 cell count as soon as HIV is diagnosed for ART naïve HIV-infected pregnant women. An alternative regimen is TDF or zidovudine (AZT) plus 3TC/FTC plus lopinavir/ritonavir (LPV/r) for HIV-infected pregnant women suspected resistant to non-nucleoside reverse transcriptase inhibitors. Treatment should be started immediately irrespective of gestational age and continued after delivery for life. Raltegravir is recommended in addition to the ART regimen for HIV-infected pregnant women who present late (gestational age (GA) ≥32 weeks) or those who have a viral load (VL) >1000 copies/mL at GA ≥32 weeks. HIV-infected pregnant women who conceive while receiving ART should continue their treatment regimen during pregnancy. HIV-infected pregnant women who present in labor and are not receiving ART should receive single-dose nevirapine immediately along with oral AZT, and continue ART for life. Infants born to HIV-infected mothers are categorized as high or standard risk for MTCT. High MTCT risk is defined as an infant whose mother has a viral load (VL) > 50 copies/mL at GA > 36 weeks or has received ART <12 weeks before delivery, or has poor ART adherence. These infants should be started on AZT plus 3TC plus NVP for 6 weeks after delivery. Infants with standard MTCT risk should receive AZT for 4 weeks. Formula feeding exclusively is recommended for all HIV-exposed infants.
Authors: K Chokephaibulkit; R Chuachoowong; T Chotpitayasunondh; S Chearskul; N Vanprapar; N Waranawat; P Mock; N Shaffer; R J Simonds Journal: AIDS Date: 2000-07-28 Impact factor: 4.177
Authors: Claire L Townsend; Laura Byrne; Mario Cortina-Borja; Claire Thorne; Annemiek de Ruiter; Hermione Lyall; Graham P Taylor; Catherine S Peckham; Pat A Tookey Journal: AIDS Date: 2014-04-24 Impact factor: 4.177
Authors: Alison L Drake; Kerry A Thomson; Caitlin Quinn; Morkor Newman Owiredu; Innocent B Nuwagira; Lastone Chitembo; Shaffiq Essajee; Rachel Baggaley; Cheryl C Johnson Journal: J Int AIDS Soc Date: 2019-04 Impact factor: 5.396
Authors: Reed A C Siemieniuk; Lyubov Lytvyn; Jinell Mah Ming; Rhonda Marama Mullen; Florence Anam; Teresia Otieno; Gordon H Guyatt; Graham P Taylor; Claudia Beltrán-Arroyave; Patrick Mbah Okwen; Ruth Nduati; John Kinuthia; Henry Namme Luma; Haresh Kirpalani; Arnaud Merglen; Olufunmilayo A Lesi; Per Olav Vandvik; Thomas Agoritsas; Susan Bewley Journal: BMJ Date: 2017-09-11
Authors: Lyubov Lytvyn; Reed A Siemieniuk; Sophie Dilmitis; Allyson Ion; Yaping Chang; Malgorzata M Bala; Veena Manja; Reza Mirza; Rene Rodriguez-Gutierrez; Hassan Mir; Regina El Dib; Laura Banfield; Per Olav Vandvik; Susan Bewley Journal: BMJ Open Date: 2017-09-11 Impact factor: 2.692